there are very few buyers - price will head lower as the previous prices probably didnt reflect fundamentals.
Printable View
Well Peb has officially won my losing horse race by being the first stock in my portfolio to hit a 50% paper loss now I can truly identify with Buffet and his quote. If you can't stand to see a stock drop 50% in value then you shouldn't be in the stock market, looks like I've passed that test but she's not an easy one to pass I might add:cool:
Previous support at 69/70 is broken. It's likely that 70c will now become a resistance level.
This stock is in dire need of a positive announcement w.r.t. sales, and it's a very long way to November.
And Moosie is loving it. ;)
I'm seeing the mid 50's as my next entry point...although if we get some very large volume north of that, I will probably lift my bid.
For now, I'm staying out. Ever since it broke through 75c on its way back down from 93c, the chart has not looked good for buying.
...or even for holding (sorry folks).
BC
It's pretty courageous trading with the SP still falling.
With the macro climate moving against growth stocks and the fact that PEB may not issue any information for a few months, I'm not sure we've seen the bottom yet.
I'm looking to re-enter this stock, but I'm not quite ready yet. I'm interested to hear other people's strategy. I'm considering 55c as this is within 10% of a major support.
In my opinion Johnny - it's not. But that doesn't mean the self confessed traders (or should that be gamblers?) won't have a crack at trading it. Some will trade on anything that moves....
However, a quick glance at the depth suggests there are a good number of "traders" still trying to exit PEB - or are they investors who are - in Balance's words - feeding the ducks?. I am sure there are some who will have their mops waiting.
Yes, would agree with that, things getting a bit thin with all the IPOs and people bailing to get into the next big thing. Then they will be bailing that IPO to get back into PEB.
Keeping some of my powder dry until things settle down.
( or up preferably).:)
Trust everything is ok in the waterworks dept, Roger, sounds as if you are by your post having no mention.
50% for cytology, 10% for Nmp22, 10% for Fish, 10% for cxbladder still leaves 20% for any others willing to claim superiority to cytology while PEB establishes itself as the best adjunct to cystoscopy available so fa la ti do.
Its not like they are trying to corner the market and anyway last year you were convinced that 30 to 40 % was quite on the cards.
Good to see you are catching up with some research. (TIC)
Keep it up
Cheers
Miner
A. I dont feel obliged to prove anything to anybody.
B. You have a bee in your bonnet about this 100 million in 5 years, its a goal, something to aim for, may be more, may be less, if you think I'm going to stand around five years from now, doing my bun because they only made 60 million or so, sorry, not going to happen.
C. We, being those that actually own shares, are moving on with a superior product, a development, a new frontier, all part of an evolution into a market that is not the same as it was. There are more patients and less urologists. With the developments worldwide in all manner of hi tech medical research the market is probably more open to new technology. I really cant say if the marketing is carried out in the same manner, not being interested in researching Matritechs methods, but suspect it would be on a par if not better.
D. I could probably be considered to have a bee in my bonnet that PEB will do quite well in the long term. They have my support albeit in a very miner capacity.:)
Pleased to see you doing and sharing a bit of research at last Snapiti. You must be wanting to buy again...
Matritech (including NMP22) was sold to Inverness, now Alere, for $36m (in shares). After paying for Employee costs and one thing or another, the net proceeds to Matritech Shareholders was expected to be around $10m.
http://www.prnewswire.com/news-relea...-58578232.html
Not much eh!
So, if Cxbladder is "only a slightly better product" then we have the mcap well wrong...
Or was the writing maybe on the wall even then? I don't know, perhaps someone could comment.
But is Cxbladder only 'slightly better"?
Have another read of the comparative results.
If you had BC, which would you choose? Seriously.
Go back to your research notes and look at NMP22 false positives.
Does it replace cytology? Could it have replaced cystoscopy?
Is the test as robust?
Is it reasonable to compare probable CXbladder sales targets to NMP22 when you consider that the market for biomarkers was perhaps in its infancy? Imagine how much harder it must have been then. And then Certndx came along with all it's claims - then abandoned when proof of clinical utility was questioned under the new CMS codes.
(sales 1.0m, 4.2m, est14.2m 2011-2013)
Sadly, the science is well beyond me, but good luck getting your head around it all.
Hi MAC
Yes it looks as if there will be a bit of a squeeze on the numbers which tightens things up nicely for PEB. I suppose eventually an equilibrium will occur, a balancing act of extremely busy urologists needing more and more tests done.
Another aspect is of course once things crank up they will need less sales force in the US and a lot of the experience could be channelled into getting the Asian side of things going. By then gastric should be about ready for commercialisation.
12 you say, crikey, things are getting wound up. Where did that come from? Dont recall seeing an announcement or anything. Convincing one urologist equivalent a month each sounds possible especially amongst 19 different and identified separate markets.
Cheers
Miner